NO330132B1 - Triazinforbindelser, farmasoytiske preparater omfattende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom - Google Patents

Triazinforbindelser, farmasoytiske preparater omfattende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom Download PDF

Info

Publication number
NO330132B1
NO330132B1 NO20050072A NO20050072A NO330132B1 NO 330132 B1 NO330132 B1 NO 330132B1 NO 20050072 A NO20050072 A NO 20050072A NO 20050072 A NO20050072 A NO 20050072A NO 330132 B1 NO330132 B1 NO 330132B1
Authority
NO
Norway
Prior art keywords
yloxy
methyl
fluoro
indol
triazin
Prior art date
Application number
NO20050072A
Other languages
English (en)
Norwegian (no)
Other versions
NO20050072L (no
Inventor
Jeffrey A Robl
Rajeev S Bhide
Zhen-Wei Cai
Ligang Qian
Louis J Lombardo
Stephanie Barbosa
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20050072L publication Critical patent/NO20050072L/no
Publication of NO330132B1 publication Critical patent/NO330132B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00ย -ย A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)
NO20050072A 2002-07-19 2005-01-06 Triazinforbindelser, farmasoytiske preparater omfattende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom NO330132B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39725602P 2002-07-19 2002-07-19
US44721303P 2003-02-13 2003-02-13
PCT/US2003/022826 WO2004009784A2 (en) 2002-07-19 2003-07-18 Novel inhibitors of kinases

Publications (2)

Publication Number Publication Date
NO20050072L NO20050072L (no) 2005-02-03
NO330132B1 true NO330132B1 (no) 2011-02-21

Family

ID=30773005

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20050072A NO330132B1 (no) 2002-07-19 2005-01-06 Triazinforbindelser, farmasoytiske preparater omfattende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
NO20050417A NO20050417L (no) 2002-07-19 2005-01-25 Azaindol kinase-inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20050417A NO20050417L (no) 2002-07-19 2005-01-25 Azaindol kinase-inhibitorer

Country Status (32)

Country Link
US (6) US6869952B2 (cg-RX-API-DMAC7.html)
EP (3) EP1539763B1 (cg-RX-API-DMAC7.html)
JP (2) JP4381978B2 (cg-RX-API-DMAC7.html)
KR (1) KR100901939B1 (cg-RX-API-DMAC7.html)
CN (3) CN1681508B (cg-RX-API-DMAC7.html)
AR (1) AR040500A1 (cg-RX-API-DMAC7.html)
AT (2) ATE505471T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003254017A1 (cg-RX-API-DMAC7.html)
BR (2) BRPI0312940B1 (cg-RX-API-DMAC7.html)
CA (2) CA2492665A1 (cg-RX-API-DMAC7.html)
CO (1) CO5680407A2 (cg-RX-API-DMAC7.html)
CY (1) CY1112628T1 (cg-RX-API-DMAC7.html)
DE (1) DE60336732D1 (cg-RX-API-DMAC7.html)
DK (1) DK1534290T3 (cg-RX-API-DMAC7.html)
ES (1) ES2377963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20074124B (cg-RX-API-DMAC7.html)
HR (2) HRP20050058A2 (cg-RX-API-DMAC7.html)
IL (3) IL166129A0 (cg-RX-API-DMAC7.html)
IS (2) IS7646A (cg-RX-API-DMAC7.html)
MX (2) MXPA05000715A (cg-RX-API-DMAC7.html)
MY (1) MY134848A (cg-RX-API-DMAC7.html)
NO (2) NO330132B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ537523A (cg-RX-API-DMAC7.html)
PE (1) PE20040680A1 (cg-RX-API-DMAC7.html)
PL (2) PL375352A1 (cg-RX-API-DMAC7.html)
PT (1) PT1534290E (cg-RX-API-DMAC7.html)
RS (2) RS20050041A (cg-RX-API-DMAC7.html)
RU (2) RU2331642C2 (cg-RX-API-DMAC7.html)
SI (1) SI1534290T1 (cg-RX-API-DMAC7.html)
TW (1) TWI329112B (cg-RX-API-DMAC7.html)
UA (1) UA82846C2 (cg-RX-API-DMAC7.html)
WO (2) WO2004009601A1 (cg-RX-API-DMAC7.html)

Families Citing this family (213)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
DE69734871D1 (de) * 1997-05-30 2006-01-19 St Microelectronics Srl Verfahren zur Herstellung eines Germanium-implantierten bipolaren Heteroรผbergangtransistors
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
EP2289894A3 (en) 2002-04-23 2011-07-20 Bristol-Myers Squibb Company Pyrrolo-triazine compounds useful as kinase inhibitors
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) * 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
KR20050099525A (ko) 2003-02-05 2005-10-13 ๋ธŒ๋ฆฌ์Šคํ†จ-๋งˆ์ด์–ด์Šค ์Šคํ… ์ปดํผ๋‹ˆ ํ”ผ๋กค๋กœํŠธ๋ฆฌ์•„์ง„ ํ‚ค๋‚˜์ œ ์–ต์ œ์ œ์˜ ์ œ์กฐ ๋ฐฉ๋ฒ•
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
US7102001B2 (en) 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7064203B2 (en) 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
CN1993130B (zh) * 2004-06-28 2010-06-23 ๅธƒ้‡Œๆ–ฏๆ‰˜ๅฐ”-่ฟˆๅฐ”ๆ–ฏๆ–ฏๅฅŽๅธƒๅ…ฌๅธ ็”จไบŽๅˆถๅค‡็จ ๅˆๆ‚็Žฏๆฟ€้…ถๆŠ‘ๅˆถๅ‰‚็š„ๆ–นๆณ•ๅ’Œไธญ้—ดไฝ“
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7102003B2 (en) 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7151176B2 (en) 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
DE102004060659A1 (de) 2004-12-15 2006-07-06 Lanxess Deutschland Gmbh Neue substituierte 1H-Pyrrolo[2,3-b]pyridine und deren Herstellung
US7534882B2 (en) 2005-04-06 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
US20060257400A1 (en) * 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
CA2608733A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
US7393667B2 (en) 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US20060288309A1 (en) * 2005-06-16 2006-12-21 Cross Charles W Jr Displaying available menu choices in a multimodal browser
CN102603581B (zh) 2005-06-22 2015-06-24 ๆ™ฎ่ŽฑๅธŒ็ง‘ๅ…ฌๅธ ไฝœไธบ่›‹็™ฝ่ดจๆฟ€้…ถๆŠ‘ๅˆถๅ‰‚็š„ๅกๅ’ฏๅนถ[2,3-b]ๅกๅ•ถ่ก็”Ÿ็‰ฉ
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
GB0517387D0 (en) * 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
ATE543914T1 (de) 2005-09-01 2012-02-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
EP1928880A1 (en) * 2005-09-27 2008-06-11 Brystol-Myers Squibb Company Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN101466710B (zh) 2005-12-02 2013-05-29 ๆ‹œๅฐ”ๅฅๅบทๆŠค็†ๆœ‰้™่ดฃไปปๅ…ฌๅธ ็”จไบŽๆฒป็–—ไธŽ่ก€็ฎก็”Ÿๆˆๆœ‰ๅ…ณ็š„่ฟ‡ๅบฆๅขžๆฎ–ๆ€ง็—…็—‡ๅ’Œ็–พ็—…็š„ๅ–ไปฃ็š„4-ๆฐจๅŸบ-ๅกๅ’ฏๅนถไธ‰ๅ—ช่ก็”Ÿ็‰ฉ
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
DE602007010734D1 (de) 2006-02-10 2011-01-05 Amgen Inc Hydratformen von amg706
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
CA2645031A1 (en) 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
EA019693B1 (ru) * 2006-04-21 2014-05-30 ะ‘ั€ะธัั‚ะพะป-ะœะฐะตั€ั ะกะบะฒะธะฑะฑ ะšะพะผะฟะฐะฝะธ ะกะŸะžะกะžะ‘ ะŸะžะ›ะฃะงะ•ะะ˜ะฏ 2-[4-(4-ะคะขะžะ -2-ะœะ•ะขะ˜ะ›-1H-ะ˜ะะ”ะžะ›-5-ะ˜ะ›ะžะšะกะ˜)-5-ะœะ•ะขะ˜ะ›ะŸะ˜ะ ะ ะžะ›ะž[2,1-f][1,2,4]ะขะ ะ˜ะะ—ะ˜ะ-6-ะ˜ะ›ะžะšะกะ˜]-1-ะœะ•ะขะ˜ะ›ะญะขะ˜ะ›ะžะ’ะžะ“ะž ะญะคะ˜ะ ะ [(1R),2S]-2-ะะœะ˜ะะžะŸะ ะžะŸะ˜ะžะะžะ’ะžะ™ ะšะ˜ะกะ›ะžะขะซ
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
CA2657594C (en) * 2006-07-07 2012-01-17 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
ES2393410T3 (es) * 2006-08-09 2012-12-21 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
BRPI0720695A2 (pt) 2006-12-21 2014-02-18 Plexxikon Inc Compostos e mรฉtodos para modulaรงรฃo de cinase, e indicaรงรตes para estes
US7851500B2 (en) 2007-01-05 2010-12-14 Bristol-Myers Squibb Company Aminopyrazole kinase inhibitors
EP2118069B1 (en) 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
US7820421B2 (en) 2007-02-08 2010-10-26 Codexis, Inc. Ketoreductases and uses thereof
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
WO2008127526A2 (en) * 2007-03-12 2008-10-23 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
EP2527467A3 (en) 2007-04-13 2013-03-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
CA2702637A1 (en) 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
US20110086850A1 (en) * 2008-04-11 2011-04-14 Board Of Regents, The University Of Texas System Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 ใ‚ชใƒผใ‚จใ‚นใ‚ขใ‚คใƒปใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซใ‚บ๏ผŒใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ้–“่‘‰ๆง˜่…ซ็˜็ดฐ่ƒžใพใŸใฏใใฎ็”Ÿๆˆใ‚’้˜ปๅฎณใ™ใ‚‹่–ฌๅ‰คใ‚’ๅŒๅฎšใ™ใ‚‹ใŸใ‚ใฎๆ–นๆณ•
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
WO2011044019A1 (en) * 2009-10-05 2011-04-14 Bristol-Myers Squibb Company (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
PH12012500900A1 (en) 2009-11-06 2012-11-12 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20120258940A1 (en) 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
CA2784807C (en) * 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2013518889A (ja) * 2010-02-03 2013-05-23 ใƒ–ใƒชใ‚นใƒˆใƒซโˆ’ใƒžใ‚คใƒคใƒผใ‚บ ใ‚นใ‚ฏใ‚คใƒ– ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ๏ผˆ๏ผณ๏ผ‰โˆ’๏ผ‘โˆ’๏ผˆ๏ผ”โˆ’๏ผˆ๏ผ•โˆ’ใ‚ทใ‚ฏใƒญใƒ—ใƒญใƒ”ใƒซโˆ’๏ผ‘๏ผจโˆ’ใƒ”ใƒฉใ‚พใƒผใƒซโˆ’๏ผ“โˆ’ใ‚คใƒซใ‚ขใƒŸใƒŽ๏ผ‰ใƒ”ใƒญใƒญ๏ผป๏ผ‘๏ผŒ๏ผ’โˆ’๏ฝ†๏ผฝ๏ผป๏ผ‘๏ผŒ๏ผ’๏ผŒ๏ผ”๏ผฝใƒˆใƒชใ‚ขใ‚ธใƒณโˆ’๏ผ’โˆ’ใ‚คใƒซ๏ผ‰โˆ’๏ผฎโˆ’๏ผˆ๏ผ–โˆ’ใƒ•ใƒซใ‚ชใƒญใƒ”ใƒชใ‚ธใƒณโˆ’๏ผ“โˆ’ใ‚คใƒซ๏ผ‰โˆ’๏ผ’โˆ’ใƒกใƒใƒซใƒ”ใƒญใƒชใ‚ธใƒณโˆ’๏ผ’โˆ’ใ‚ซใƒซใƒœใ‚ญใ‚ตใƒŸใƒ‰ใฎ็ตๆ™ถๅฝข
JP5093527B2 (ja) * 2010-02-10 2012-12-12 ๆ—ฅๆœฌ้›ปๆฐ—ๆ ชๅผไผš็คพ ่ค‡ๅˆๅ…‰ๅฐŽๆณข่ทฏใ€ๆณข้•ทๅฏๅค‰ใƒ•ใ‚ฃใƒซใ‚ฟใ€ๆณข้•ทๅฏๅค‰ใƒฌใƒผใ‚ถใ€ใŠใ‚ˆใณๅ…‰้›†็ฉๅ›ž่ทฏ
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palackรฝ University in Olomouc Targeting of vegfr2
US20130178517A1 (en) * 2010-07-09 2013-07-11 Richard L. Atkinson Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions
US8338771B2 (en) * 2010-11-05 2012-12-25 Green Plus Co., Ltd. Apparatus for tracking and condensing sunlight of sliding type
LT2672967T (lt) 2011-02-07 2018-12-10 Plexxikon Inc. Junginiai ir bลซdai skirti kinazฤ—s moduliavimui, ir jลณ indikacijos
TWI558702B (zh) 2011-02-21 2016-11-21 ๆ™ฎ้›ท่พ›่‚ฏๅ…ฌๅธ ้†ซ่—ฅๆดปๆ€ง็‰ฉ่ณช็š„ๅ›บๆ…‹ๅฝขๅผ
ES2543569T3 (es) 2011-03-23 2015-08-20 Amgen Inc. Inhibidores duales tricรญclicos condensados de CDK 4/6 y FLT3
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN103450204B (zh) 2012-05-31 2016-08-17 ไธญๅ›ฝ็ง‘ๅญฆ้™ขไธŠๆตท่ฏ็‰ฉ็ ”็ฉถๆ‰€ ๅกๅ’ฏ[2๏ผŒ1-f][1๏ผŒ2๏ผŒ4]ๅนถไธ‰ๅ—ช็ฑปๅŒ–ๅˆ็‰ฉ๏ผŒๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅŠ็”จ้€”
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN102675323B (zh) * 2012-06-01 2014-04-09 ๅ—ไบฌ่ฏ็Ÿณ่ฏ็‰ฉ็ ”ๅ‘ๆœ‰้™ๅ…ฌๅธ ๅกๅ’ฏๅนถ[2,1-f][1,2,4]ไธ‰ๅ—ช่ก็”Ÿ็‰ฉๅŠๅ…ถๆŠ—่‚ฟ็˜ค็”จ้€”
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
CN103664957A (zh) * 2012-09-25 2014-03-26 ๆจๅญๅจ‡ ไธ€็ฑปๆฒป็–—ๆˆฟ่ง’็‹ญ็ช„็š„ๅŒ–ๅˆ็‰ฉๅŠๅ…ถ็”จ้€”
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
FR3000494B1 (fr) * 2012-12-28 2015-08-21 Oribase Pharma Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9688662B2 (en) 2013-04-04 2017-06-27 Janssen Pharmaceutica Nv N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
JPWO2015056782A1 (ja) * 2013-10-17 2017-03-09 ๅกฉ้‡Ž็พฉ่ฃฝ่–ฌๆ ชๅผไผš็คพ ๆ–ฐ่ฆใ‚ขใƒซใ‚ญใƒฌใƒณ่ช˜ๅฐŽไฝ“
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (es) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Compuestos heteroatรณmicos รบtiles para el tratamiento de enfermedades proliferativas
CN104725381B (zh) * 2013-12-19 2018-04-10 ๅ—ไบฌๅœฃๅ’Œ่ฏไธš่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็”Ÿ้•ฟๅ› ๅญๅ—ไฝ“ๆŠ‘ๅˆถๅ‰‚ๅŠๅ…ถๅบ”็”จ
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107517589A (zh) 2015-01-08 2017-12-26 ๅฐๅˆฉๅ…ฐยทๆ–ฏๅฆ็ฆๅคงๅญฆๆ‰˜็ฎกๅง”ๅ‘˜ไผš ๆไพ›้ชจใ€้ชจ้ซ“ๅŠ่ฝฏ้ชจ็š„่ฏฑๅฏผ็š„ๅ› ๅญๅ’Œ็ป†่ƒž
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ใƒ€ใƒŠ๏ผใƒ•ใ‚กใƒผใƒใƒผ ใ‚ญใƒฃใƒณใ‚ตใƒผ ใ‚คใƒณใ‚นใƒ†ใ‚ฃใƒ†ใƒฅใƒผใƒˆ๏ผŒ ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใ‚ตใ‚คใ‚ฏใƒชใƒณไพๅญ˜ๆ€งใ‚ญใƒŠใƒผใ‚ผใฎ้˜ปๅฎณๅ‰ค
EP3356345B1 (en) 2015-09-30 2023-11-08 Max-Planck-Gesellschaft zur Fรถrderung der Wissenschaften e.V. Heteroaryl derivatives as sepiapterin reductase inhibitors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7085985B2 (ja) 2016-03-04 2022-06-17 ๅคง้ตฌ่–ฌๅ“ๅทฅๆฅญๆ ชๅผไผš็คพ ๆ‚ชๆ€ง่…ซ็˜ๆฒป็™‚็”จ่ฃฝๅ‰คๅŠใณ็ต„ๆˆ็‰ฉ
LT3450436T (lt) * 2016-04-28 2022-09-12 Takeda Pharmaceutical Company Limited Kondensuotas heterociklinis junginys
MX391651B (es) * 2016-12-16 2025-03-21 Cystic Fibrosis Found Derivados de heteroarilo biciclico como potenciadores de cftr.
KR20250152110A (ko) 2016-12-22 2025-10-22 ์•”์   ์ธํฌ ํ์•”, ์ทŒ์žฅ์•” ๋˜๋Š” ๋Œ€์žฅ์•”์„ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•œ kras g12c ์–ต์ œ์ œ๋กœ์„œ์˜ ๋ฒค์ฆˆ์ด์†Œํ‹ฐ์•„์กธ, ์ด์†Œํ‹ฐ์•„์กธ๋กœ[3,4-b]ํ”ผ๋ฆฌ๋”˜, ํ€ด๋‚˜์กธ๋ฆฐ, ํ”„ํƒˆ๋ผ์ง„, ํ”ผ๋ฆฌ๋„[2,3-d]ํ”ผ๋ฆฌ๋‹ค์ง„ ๋ฐ ํ”ผ๋ฆฌ๋„[2,3-d]ํ”ผ๋ฆฌ๋ฏธ๋”˜ ์œ ๋„์ฒด
CN110139865B (zh) * 2016-12-29 2022-02-18 ็Ÿณ่ฏ้›†ๅ›ขไธญๅฅ‡ๅˆถ่ฏๆŠ€ๆœฏ๏ผˆ็Ÿณๅฎถๅบ„๏ผ‰ๆœ‰้™ๅ…ฌๅธ FgfrๆŠ‘ๅˆถๅ‰‚
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc ู…ุซุจุทุงุช kras g12c ูˆุทุฑู‚ ู„ุงุณุชุฎุฏุงู…ู‡ุง
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
KR102473372B1 (ko) 2018-03-19 2022-12-05 ๋‹ค์ดํ˜ธ์•ผ์ฟ ํžŒ๊ณ ๊ต ๊ฐ€๋ถ€์‹œํ‚ค๊ฐ€์ด์ƒค ์•Œํ‚ฌํ™ฉ์‚ฐ๋‚˜ํŠธ๋ฅจ์„ ํฌํ•จํ•˜๋Š” ์˜์•ฝ ์กฐ์„ฑ๋ฌผ
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y mรฉtodos de uso de los mismos
EP3802537A1 (en) 2018-06-11 2021-04-14 Amgen Inc. Kras g12c inhibitors for treating cancer
EP3807276B1 (en) 2018-06-12 2025-12-10 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CN112367991A (zh) 2018-06-25 2021-02-12 ่พพ็บณ-ๆณ•ไผฏ็™Œ็—‡็ ”็ฉถๆ‰€่‚กไปฝๆœ‰้™ๅ…ฌๅธ Taireๅฎถๆ—ๆฟ€้…ถๆŠ‘ๅˆถๅ‰‚ๅŠๅ…ถ็”จ้€”
JP7516029B2 (ja) 2018-11-16 2024-07-16 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ๏ผซ๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝƒ้˜ปๅฎณๅ‰คๅŒ–ๅˆ็‰ฉใฎ้‡่ฆใชไธญ้–“ไฝ“ใฎๆ”น่‰ฏๅˆๆˆๆณ•
JP7377679B2 (ja) 2018-11-19 2023-11-10 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ใŒใ‚“ๆฒป็™‚ใฎใŸใ‚ใฎ๏ฝ‹๏ฝ’๏ฝ๏ฝ“๏ฝ‡๏ผ‘๏ผ’๏ฝƒ้˜ปๅฎณๅ‰คๅŠใณ๏ผ‘็จฎไปฅไธŠใฎ่–ฌๅญฆ็š„ใซๆดปๆ€งใช่ฟฝๅŠ ใฎ่–ฌๅ‰คใ‚’ๅซใ‚€ไฝต็”จ็™‚ๆณ•
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
US12459932B2 (en) 2018-12-20 2025-11-04 Amgen Inc. KIF18A inhibitors
EP3897852A1 (en) 2018-12-20 2021-10-27 Amgen Inc. Kif18a inhibitors
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
CA3123227A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
US20230096028A1 (en) 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP4306529A3 (en) * 2019-05-13 2024-04-10 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
PH12021552922A1 (en) 2019-05-21 2022-04-04 Amgen Inc Solid state forms
JP7756070B2 (ja) 2019-08-02 2025-10-17 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ๏ผซ๏ฝ‰๏ฝ†๏ผ‘๏ผ˜๏ฝ้˜ปๅฎณๅ‰คใจใ—ใฆใฎใƒ”ใƒชใ‚ธใƒณ่ช˜ๅฐŽไฝ“
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114401953A (zh) 2019-08-02 2022-04-26 ็พŽๅ›ฝๅฎ‰่ฟ›ๅ…ฌๅธ Kif18aๆŠ‘ๅˆถๅ‰‚
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
JP7634003B2 (ja) 2019-10-24 2025-02-20 ใ‚ขใƒ ใ‚ธใ‚จใƒณใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ใŒใ‚“ใฎๆฒป็™‚ใซใŠใ‘ใ‚‹๏ฝ‹๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝƒๅŠใณ๏ฝ‹๏ฝ’๏ฝ๏ฝ“ ๏ฝ‡๏ผ‘๏ผ’๏ฝ„้˜ปๅฎณๅ‰คใจใ—ใฆๆœ‰็”จใชใƒ”ใƒชใƒ‰ใƒ”ใƒชใƒŸใ‚ธใƒณ่ช˜ๅฐŽไฝ“
TW202132315A (zh) 2019-11-04 2021-09-01 ็พŽๅ•†้Šณๆ–ฐ้†ซ่—ฅๅ…ฌๅธ Ras ๆŠ‘ๅˆถๅŠ‘
CN115873067A (zh) 2019-11-04 2023-03-31 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ RasๆŠ‘ๅˆถๅ‰‚
AU2020379734B2 (en) 2019-11-04 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicรญclicos y usos de estos.
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
US12473281B2 (en) 2019-11-14 2025-11-18 Amgen Inc. Synthesis of KRAS G12C inhibitor compound
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Sรญntese melhorada de composto inibidor de kras g12c
DK4063364T3 (da) * 2019-11-18 2024-11-25 Jumbo Drug Bank Co Ltd Pyrrolotriazinforbindelse fungerende som mnk-inhibitor
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CA3163703A1 (en) 2020-01-07 2021-07-15 Steve Kelsey Shp2 inhibitor dosing and methods of treating cancer
CN115916194A (zh) 2020-06-18 2023-04-04 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ ็”จไบŽๅปถ่ฟŸใ€้ข„้˜ฒๅ’Œๆฒป็–—้’ˆๅฏนrasๆŠ‘ๅˆถๅ‰‚็š„่Žทๅพ—ๆ€งๆŠ—ๆ€ง็š„ๆ–นๆณ•
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
CN117683049A (zh) 2020-09-15 2024-03-12 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ ไฝœไธบrasๆŠ‘ๅˆถๅ‰‚ไปฅๆฒป็–—็™Œ็—‡็š„ๅฒๅ“š่ก็”Ÿ็‰ฉ
WO2022140427A1 (en) 2020-12-22 2022-06-30 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
EP4334325A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US20230106174A1 (en) 2021-05-05 2023-04-06 Revolution Medicines, Inc. Ras inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
AU2022379973A1 (en) 2021-11-08 2024-06-27 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
TW202346267A (zh) 2022-03-07 2023-12-01 ็พŽๅ•†ๅฎ‰้€ฒๅ…ฌๅธ ็”จๆ–ผ่ฃฝๅ‚™๏ผ”๏ผ็”ฒๅŸบ๏ผ๏ผ’๏ผไธ™๏ผ๏ผ’๏ผๅŸบ๏ผๅกๅ•ถ๏ผ๏ผ“๏ผ็”ฒ่…ˆไน‹ๆ–นๆณ•
EP4489755A1 (en) 2022-03-08 2025-01-15 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
KR20250007533A (ko) 2022-04-08 2025-01-14 ์ƒค์ด ํ…Œ๋ผํ“จํ‹ฑ์Šค ์—˜์—˜์”จ ์•”, ์—ผ์ฆ์„ฑ ์งˆํ™˜, ras์งˆํ™˜ ๋ฐ ์„ฌ์œ ์„ฑ ์งˆํ™˜์˜ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ras ์ŠˆํผํŒจ๋ฐ€๋ฆฌ ๋‹จ๋ฐฑ์งˆ๊ณผ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ํ™”ํ•ฉ๋ฌผ
CA3256230A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATE
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2023358792A1 (en) 2022-10-14 2025-04-17 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024112656A1 (en) * 2022-11-21 2024-05-30 The Board Of Trustees Of The Leland Stanford Junior University Use of a tyrosine kinase inhibitor for the treatment of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension
KR20250164828A (ko) 2023-03-30 2025-11-25 ๋ ˆ๋ณผ๋ฃจ์…˜ ๋ฉ”๋””์Šจ์ฆˆ, ์ธํฌ. Ras gtp ๊ฐ€์ˆ˜๋ถ„ํ•ด ์œ ๋„๋ฅผ ์œ„ํ•œ ์กฐ์„ฑ๋ฌผ ๋ฐ ์ด์˜ ์šฉ๋„
AU2024243852A1 (en) 2023-04-07 2025-11-06 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121100123A (zh) 2023-04-14 2025-12-09 ้”ๆ–ฐๅŒป่ฏๅ…ฌๅธ RasๆŠ‘ๅˆถๅ‰‚็š„็ป“ๆ™ถๅฝขๅผ
TW202448897A (zh) 2023-04-14 2024-12-16 ็พŽๅ•†้Šณๆ–ฐ้†ซ่—ฅๅ…ฌๅธ ๏ผฒ๏ฝ๏ฝ“ๆŠ‘ๅˆถๅŠ‘ไน‹็ตๆ™ถๅฝขๅผใ€ๅซๆœ‰ๅ…ถไน‹็ต„ๅˆ็‰ฉๅŠๅ…ถไฝฟ็”จๆ–นๆณ•
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116813526A (zh) * 2023-05-22 2023-09-29 ๅ››ๅท็œๅŒปๅญฆ็ง‘ๅญฆ้™ขยทๅ››ๅท็œไบบๆฐ‘ๅŒป้™ข ๅผ‚ๅฒๅ“šๅ•‰้…ฎ็ฑปๅŒ–ๅˆ็‰ฉใ€ๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅŠๅ…ถๅบ”็”จ
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025080653A1 (en) * 2023-10-10 2025-04-17 Shy Therapeutics, Llc Pyrrolo[2,1-f][1,2,4]triazine compounds acting against cancers, inflammatory diseases, and fibrotic disease via interaction with ras superfamily proteins
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (20)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
HUT70208A (en) * 1992-09-25 1995-09-28 Lilly Co Eli Process for preparing 5-substituted pyrrolo[2,3-d]-pyrimidines
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
RU2331640C2 (ru) * 1999-05-21 2008-08-20 ะ‘ั€ะธัั‚ะพะป-ะœะฐะตั€ั ะกะบะฒะธะฑะฑ ะšะพ. ะŸะธั€ั€ะพะปั‚ั€ะธะฐะทะธะฝะพะฒั‹ะต ะธะฝะณะธะฑะธั‚ะพั€ั‹ ะบะธะฝะฐะท
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
AU6473600A (en) * 1999-08-23 2001-03-19 Shionogi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
GB0017256D0 (en) * 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
BR0113078A (pt) * 2000-08-09 2003-07-01 Astrazeneca Ab Uso de um composto, composto, processo para a preparaรงรฃo do mesmo, composiรงรฃo farmacรชutica, e, mรฉtodo para produzir um efeito antiangiogรชnico e/ou redutor da permeabilidade vascular em um animal de sangue quente
AU3276002A (en) * 2000-11-17 2002-05-27 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) * 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
EP2289894A3 (en) * 2002-04-23 2011-07-20 Bristol-Myers Squibb Company Pyrrolo-triazine compounds useful as kinase inhibitors
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TW200407143A (en) * 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US6933386B2 (en) * 2002-07-19 2005-08-23 Bristol Myers Squibb Company Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
KR20050099525A (ko) * 2003-02-05 2005-10-13 ๋ธŒ๋ฆฌ์Šคํ†จ-๋งˆ์ด์–ด์Šค ์Šคํ… ์ปดํผ๋‹ˆ ํ”ผ๋กค๋กœํŠธ๋ฆฌ์•„์ง„ ํ‚ค๋‚˜์ œ ์–ต์ œ์ œ์˜ ์ œ์กฐ ๋ฐฉ๋ฒ•

Also Published As

Publication number Publication date
RU2005104818A (ru) 2005-07-20
IS7646A (is) 2005-01-12
AU2003254088A1 (en) 2004-02-09
JP2005538990A (ja) 2005-12-22
SI1534290T1 (sl) 2012-05-31
WO2004009784A3 (en) 2004-04-22
ATE537843T1 (de) 2012-01-15
EP2280012A2 (en) 2011-02-02
DE60336732D1 (de) 2011-05-26
EP1534290A2 (en) 2005-06-01
HRP20050059A2 (en) 2005-04-30
US7521450B2 (en) 2009-04-21
HK1072545A1 (en) 2005-09-02
IL166232A0 (en) 2006-01-15
PL216663B1 (pl) 2014-04-30
CA2492804A1 (en) 2004-01-29
IS2880B (is) 2014-05-15
BRPI0312940B8 (cg-RX-API-DMAC7.html) 2021-05-25
US20040063707A1 (en) 2004-04-01
IS7647A (is) 2005-01-12
CY1112628T1 (el) 2016-02-10
JP2005538989A (ja) 2005-12-22
AR040500A1 (es) 2005-04-06
US20070299075A1 (en) 2007-12-27
US20090170853A1 (en) 2009-07-02
KR100901939B1 (ko) 2009-06-10
GEP20074213B (en) 2007-10-10
US6969717B2 (en) 2005-11-29
CN101880283A (zh) 2010-11-10
EP1539763B1 (en) 2011-04-13
EP2280012A3 (en) 2011-05-18
US20050124621A1 (en) 2005-06-09
WO2004009601A1 (en) 2004-01-29
RU2005104422A (ru) 2005-08-10
NO20050072L (no) 2005-02-03
RS20050042A (sr) 2007-06-04
KR20080095906A (ko) 2008-10-29
CN101880283B (zh) 2012-07-18
GEP20074124B (en) 2007-06-11
US20060058304A1 (en) 2006-03-16
JP4381978B2 (ja) 2009-12-09
NO20050417L (no) 2005-02-17
IL166129A (en) 2015-04-30
HRP20050059B8 (hr) 2016-03-25
JP4361485B2 (ja) 2009-11-11
RS52325B (sr) 2012-12-31
IL166129A0 (en) 2006-01-15
HRP20050058A2 (en) 2005-08-31
EP1534290B1 (en) 2011-12-21
EP1539763A1 (en) 2005-06-15
HRP20050059B1 (hr) 2015-02-27
US6869952B2 (en) 2005-03-22
UA82846C2 (en) 2008-05-26
US7820814B2 (en) 2010-10-26
CA2492804C (en) 2009-06-23
TW200412973A (en) 2004-08-01
CN1681508A (zh) 2005-10-12
CA2492665A1 (en) 2004-01-29
MY134848A (en) 2007-12-31
ES2377963T3 (es) 2012-04-03
MXPA05000715A (es) 2006-02-22
TWI329112B (en) 2010-08-21
PE20040680A1 (es) 2004-10-08
BRPI0312940B1 (pt) 2019-07-23
WO2004009784A2 (en) 2004-01-29
EP1534290A4 (en) 2006-11-29
AU2003254088B2 (en) 2008-07-17
EP1539763A4 (en) 2007-08-01
PL375352A1 (en) 2005-11-28
NZ537523A (en) 2007-08-31
US20040072832A1 (en) 2004-04-15
BR0312801A (pt) 2007-06-26
CO5680407A2 (es) 2006-09-29
RS20050041A (sr) 2007-06-04
MXPA05000716A (es) 2005-04-08
CN1315833C (zh) 2007-05-16
PL375389A1 (en) 2005-11-28
AU2003254017A1 (en) 2004-02-09
RU2331642C2 (ru) 2008-08-20
CN1681508B (zh) 2010-10-06
DK1534290T3 (da) 2012-04-10
ATE505471T1 (de) 2011-04-15
US7265113B2 (en) 2007-09-04
BR0312940A (pt) 2005-06-21
CN1681818A (zh) 2005-10-12
PT1534290E (pt) 2012-03-05

Similar Documents

Publication Publication Date Title
NO330132B1 (no) Triazinforbindelser, farmasoytiske preparater omfattende slike, slike forbindelser for anvendelse som medikament samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
US6933386B2 (en) Process for preparing certain pyrrolotriazine compounds
EP1543009A1 (en) Pyrrolotriazine kinase inhibitors
KR100869417B1 (ko) ์‹ ๊ทœํ•œ ํ‚ค๋‚˜์ œ ์–ต์ œ์ œ
HK1072545B (en) Novel inhibitors of kinases
KR20050019903A (ko) ์•„์ž์ธ๋Œ ํ‚ค๋‚˜์•„์ œ ์–ต์ œ์ œ
KR20050018963A (ko) ํŠน์ • ํ”ผ๋กค๋กœํŠธ๋ฆฌ์•„์ง„ ํ™”ํ•ฉ๋ฌผ์˜ ์ œ์กฐ ๋ฐฉ๋ฒ•

Legal Events

Date Code Title Description
MK1K Patent expired